List of Excipients in Branded Drug TENEX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Promius Pharma LLC	TENEX	guanfacine hydrochloride	67857-705	ANHYDROUS LACTOSE
Promius Pharma LLC	TENEX	guanfacine hydrochloride	67857-705	CELLULOSE, MICROCRYSTALLINE
Promius Pharma LLC	TENEX	guanfacine hydrochloride	67857-705	FD&C RED NO. 40
Promius Pharma LLC	TENEX	guanfacine hydrochloride	67857-705	POVIDONE
Promius Pharma LLC	TENEX	guanfacine hydrochloride	67857-705	STEARIC ACID

TENEX Excipient Strategy and Commercial Opportunities for Guanfacine Immediate-Release Tablets

Last updated: September 24, 2026

Tenex is the former U.S. brand for guanfacine hydrochloride immediate-release tablets, an orally administered alpha-2A adrenergic receptor agonist. Its original commercial formulation used conventional tablet excipients, including lactose, microcrystalline cellulose, povidone, and stearic acid. The brand has no meaningful remaining market exclusivity; commercial opportunity is concentrated in differentiated generic, pediatric, adherence, and specialized dosage-form products rather than in traditional brand substitution.

What drug and dosage form does Tenex represent?

Tenex contains guanfacine hydrochloride in immediate-release tablet strengths, historically including 1 mg and 2 mg tablets. Guanfacine is used for hypertension and has also been used off-label in attention-deficit/hyperactivity disorder, particularly when sedation, impulsivity, sleep disturbance, or stimulant intolerance are commercial and clinical considerations.

Tenex should not be confused with Intuniv, the extended-release guanfacine product. The two products contain the same active moiety but use different release profiles, administration instructions, pharmacokinetic objectives, and regulatory positioning.

Attribute	Tenex	Intuniv
Active ingredient	Guanfacine hydrochloride	Guanfacine hydrochloride
Release type	Immediate release	Extended release
Historical dosage forms	Tablets	Extended-release tablets
Primary branded indication	Hypertension	ADHD
Main commercial substitutes	Generic guanfacine IR	Generic guanfacine ER
Key formulation issue	Conventional tablet performance and tolerability	Controlled-release matrix and dose dumping risk

The Tenex labeling identifies lactose, microcrystalline cellulose, povidone, and stearic acid among the tablet’s inactive ingredients.[1]

What excipients protect or enable the Tenex formulation?

The historical Tenex excipient system is technically conventional and provides limited formulation differentiation.

Excipient	Likely function	Commercial relevance
Lactose	Diluent and tablet bulking agent	Low-cost, familiar, but unsuitable for patients with certain intolerance concerns
Microcrystalline cellulose	Diluent, dry binder, disintegration support	Supports direct compression and robust tablet manufacture
Povidone	Binder	Improves granule or tablet mechanical strength
Stearic acid	Lubricant	Supports ejection from the tablet press

The formulation’s simplicity lowers manufacturing barriers. It also limits the scope for a generic company to claim meaningful product differentiation through ordinary substitution of one filler, binder, or lubricant.

The strongest excipient opportunities are therefore linked to patient-facing performance:

• lactose-free tablets;
• low-dose pediatric tablets with improved content uniformity;
• orally disintegrating tablets;
• mini-tablets;
• chewable or dispersible tablets;
• taste-masked pediatric products;
• tablets designed for easier swallowing;
• formulations with reduced friability or improved stability;
• fixed-dose or co-packaged regimens for hypertension or ADHD-related care.

What excipient strategy is appropriate for generic Tenex?

A conventional immediate-release generic should prioritize regulatory simplicity, bioequivalence, supply security, and low manufacturing cost.

First-line formulation strategy

A practical baseline formulation would use:

• microcrystalline cellulose as the principal diluent;
• lactose or a lactose-free alternative such as mannitol, dibasic calcium phosphate, or additional microcrystalline cellulose;
• povidone or copovidone as binder where granulation is required;
• croscarmellose sodium or sodium starch glycolate if disintegration requires improvement;
• magnesium stearate or stearic acid as lubricant;
• a film coat only if needed for identification, handling, or taste control.

For an ANDA, the formulation should remain close to the reference product where feasible. FDA permits inactive-ingredient differences in generic products, but the applicant must demonstrate pharmaceutical equivalence, bioequivalence, acceptable labeling, and suitability of the proposed ingredients for the route and dosage form.[2]

Lactose-free opportunity

A lactose-free guanfacine IR tablet is commercially credible because the historical Tenex formulation included lactose. A lactose-free product could target:

• patients reporting lactose sensitivity;
• pediatric prescribers seeking simplified excipient profiles;
• institutional formularies with excipient restrictions;
• private-label and specialty pharmacy channels.

The opportunity is commercially moderate rather than transformative. Lactose is widely accepted in oral tablets, and many patients do not require a lactose-free formulation. The product would need a clear supply, price, or patient-adherence advantage.

Mannitol-based strategy

Mannitol can support a cleaner sensory profile and is widely used in orally disintegrating and chewable products. Its cooling sensation can improve mouthfeel, although the formulation must control friability, hygroscopicity, and compression behavior.

A mannitol-based tablet could support a product positioned around:

• rapid disintegration;
• water-free administration;
• pediatric use;
• geriatric swallowing difficulty.

The developer would need to establish that the dosage form does not create unacceptable buccal absorption, altered exposure, or variable dosing relative to the reference tablet.

What formulation patents could protect a new guanfacine product?

A routine excipient substitution is unlikely to produce a strong composition-of-matter or formulation patent. Patentable differentiation would more likely require a defined technical effect tied to a specific composition or process.

Potential claim areas include:

1. Orally disintegrating formulations. Claims could cover a defined guanfacine particle size, porous matrix, superdisintegrant concentration, hardness range, and disintegration time.

2. Taste-masked pediatric formulations. Protection could focus on polymer coating, ion-exchange resin complexation, lipid coating, or a multiparticulate system that reduces bitterness without materially delaying release.

3. Mini-tablets and sprinkle products. Claims could cover dose-uniform multiparticulates that can be administered with soft food.

4. Modified-release formulations. These would compete directly with Intuniv-type products and require stronger pharmacokinetic and clinical differentiation.

5. Stability-enhanced formulations. Patentability may arise from a specific moisture-control system, antioxidant package, coating, or packaging combination that reduces degradation.

6. Combination products. Guanfacine combined with a stimulant or another ADHD therapy could support method-of-treatment and formulation claims, subject to clinical and regulatory requirements.

A patent strategy should avoid relying solely on broad claims to common excipients. Such claims face substantial prior-art and obviousness risk. Stronger positions require measurable advantages such as faster disintegration, improved dose uniformity, reduced bitterness, improved stability, or a clinically relevant pharmacokinetic profile.

When does Tenex lose exclusivity, and what is its Orange Book status?

Tenex has effectively lost U.S. market exclusivity. The product is an old immediate-release drug, and generic guanfacine hydrochloride tablets are available. The main commercial question is therefore not branded patent expiration but whether a new formulation can obtain differentiated labeling, pricing, distribution, or market access.

The relevant regulatory distinctions are:

Exclusivity issue	Tenex commercial position
New chemical entity exclusivity	Expired
Original brand patent protection	Expired or commercially immaterial
Current generic competition	Established
New formulation exclusivity	Possible only for a separately approved product
Pediatric exclusivity	Not a current basis for Tenex market protection
Orphan exclusivity	Not applicable to the core Tenex product

The FDA Orange Book remains the controlling source for current reference-product, patent, exclusivity, and therapeutic-equivalence information.[3] A new applicant should not assume that historical Tenex labeling creates an active patent barrier. It should review the current Orange Book listing for the relevant reference product and any patents or exclusivities associated with guanfacine products.

Are there Paragraph IV challenges involving Tenex?

Paragraph IV litigation is not the principal risk for a conventional Tenex generic because guanfacine IR has long been subject to generic competition. The more relevant Paragraph IV exposure would arise if a company targets:

• a currently protected guanfacine extended-release product;
• a newly approved pediatric formulation;
• an active method-of-use patent;
• a later-listed formulation patent;
• a licensed delivery system.

An ANDA applicant seeking approval before listed patent expiry would need to evaluate certification strategy under 21 U.S.C. §355(j). A Paragraph IV notice could trigger patent litigation and a 30-month stay in the circumstances defined by the Hatch-Waxman statute.[4]

For a new guanfacine IR product, the practical litigation risk is more likely to involve formulation patents owned by a competing developer than legacy Tenex patents.

What commercial opportunities exist for guanfacine excipient innovation?

Pediatric ADHD products

The strongest opportunity is a child-oriented dosage form. Guanfacine is used in pediatric ADHD management, and swallowing difficulty, dose titration, sedation, and adherence are recurring product-design considerations.

Potential products include:

• 0.25 mg, 0.5 mg, and 1 mg mini-tablets;
• orally disintegrating tablets;
• chewable tablets;
• sprinkle capsules;
• taste-masked granules;
• flexible-dose blister packs.

Any pediatric product must control dose uniformity at low strengths. A 0.25 mg tablet contains a small quantity of active ingredient, increasing the importance of blending, segregation control, sampling, and content-uniformity validation.

Geriatric and dysphagia markets

Geriatric patients and patients with dysphagia create demand for smaller tablets, rapidly disintegrating tablets, and products that can be administered with water or soft food. A lactose-free and easy-swallow formulation could support institutional purchasing and specialty pharmacy distribution.

Private-label and contract manufacturing

Because the base formulation is uncomplicated, contract manufacturers could offer guanfacine IR as part of a broader cardiovascular or CNS portfolio. Commercial value would depend on:

• reliable API sourcing;
• dual-source excipient qualification;
• low minimum order quantities;
• scalable compression capacity;
• packaging that limits moisture exposure;
• rapid regulatory support for multiple strengths.

Combination and adherence products

Guanfacine can be evaluated for co-packaging with stimulant therapy or antihypertensive regimens. A co-packaged product is generally easier to commercialize than a fixed-dose combination because it reduces formulation and clinical-development complexity. A true fixed-dose combination would require a stronger clinical and regulatory justification.

How does Tenex compare with Intuniv from an excipient and patent perspective?

Intuniv is the more technically defensible target because extended release creates formulation-specific barriers. Its commercial protection has historically depended more heavily on release-control technology, clinical positioning, and regulatory exclusivity than Tenex’s conventional tablet platform.

Factor	Tenex IR	Intuniv ER
Formulation complexity	Low	Moderate to high
Excipient differentiation	Limited	Central to release profile
Pediatric positioning	Mostly generic or off-label historically	Core labeled market
Patent opportunity	Pediatric delivery and taste masking	Matrix design, release control, dosing regimen
Generic barrier	Bioequivalence and manufacturing	Bioequivalence plus release-performance complexity
Commercial margin potential	Low to moderate	Higher if differentiation is defensible

A company seeking durable IP should generally target a technically differentiated guanfacine dosage form rather than reproduce Tenex’s historical tablet composition.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are low for standard immediate-release tablets. The main execution risks are:

• API content uniformity at low dose;
• blend segregation;
• tablet weight and hardness control;
• dissolution consistency;
• impurity and stability management;
• lubricant overmixing;
• packaging protection;
• pediatric taste masking without delayed release.

IP barriers are higher for:

• modified release;
• multiparticulate delivery;
• taste masking;
• fixed-dose combinations;
• branded pediatric products;
• clinically supported dosing regimens.

Manufacturing-process patents could cover granulation conditions, particle-size distributions, coating parameters, or compression profiles. Their value depends on whether the process is necessary to achieve a measurable product advantage and whether competitors can design around it.

Which companies are challenging or competing with Tenex?

The core competitive field is generic guanfacine hydrochloride rather than branded Tenex. Competition typically comes from generic manufacturers, authorized distributors, contract manufacturers, and suppliers serving retail, institutional, and specialty channels.

The more strategically important competitor set includes manufacturers of:

• guanfacine IR tablets;
• guanfacine ER tablets;
• stimulant ADHD products;
• nonstimulant ADHD products;
• clonidine immediate-release and extended-release products.

A new Tenex-oriented product would compete on availability, formulary economics, pediatric usability, and supply reliability. A conventional tablet is unlikely to command a premium without a differentiated label or delivery feature.

What generic launch risks exist?

A standard generic launch faces limited legal risk but significant commercial risk:

• low reimbursement ceilings;
• multiple generic competitors;
• pharmacy substitution;
• limited prescriber awareness;
• low annual treatment cost;
• API price volatility;
• wholesaler concentration;
• difficulty securing favorable shelf placement.

A differentiated pediatric formulation faces higher development risk but may support better pricing and reduced direct substitution. The most credible launch sequence is a low-cost IR generic followed by a pediatric or adherence-oriented product, provided the first product generates sufficient market access and prescriber data.

Key Takeaways

• Tenex is guanfacine hydrochloride immediate-release tablets, not guanfacine extended-release.
• The historical excipient system used lactose, microcrystalline cellulose, povidone, and stearic acid.
• Conventional excipient substitution offers limited patent strength and limited pricing power.
• The strongest commercial opportunities are lactose-free, orally disintegrating, chewable, mini-tablet, sprinkle, and taste-masked pediatric products.
• Generic competition is established, and Tenex has no meaningful remaining brand exclusivity.
• A new product should target a measurable technical advantage, not merely a different filler or lubricant.
• Intuniv-type extended-release formulation development has higher technical and IP value than a routine Tenex-equivalent tablet.
• Paragraph IV risk is more relevant to protected guanfacine ER or newly patented formulations than to legacy Tenex IR.
• Commercial success depends on pediatric usability, supply reliability, reimbursement strategy, and regulatory differentiation.

FAQs

Is Tenex the same as Intuniv?

No. Both contain guanfacine hydrochloride, but Tenex is immediate release and Intuniv is extended release. They are not interchangeable on a milligram-for-milligram basis without clinical direction.

Can a lactose-free guanfacine tablet obtain formulation patent protection?

Possibly, but lactose removal alone is unlikely to provide strong patent protection. A stronger application would tie the lactose-free composition to a demonstrated technical benefit, such as improved stability, disintegration, taste, or content uniformity.

Is an orally disintegrating guanfacine tablet commercially viable?

Yes, particularly for pediatric and dysphagia markets. Commercial viability depends on taste masking, dose uniformity, stability, bioequivalence, and the ability to secure differentiated reimbursement.

Does guanfacine have biosimilar risk?

No. Guanfacine hydrochloride is a small-molecule drug, so biosimilar regulation does not apply. Competition proceeds through generic drug pathways, including ANDAs.

Can an excipient change trigger a new FDA approval for guanfacine?

A material formulation change may require an ANDA supplement, a new ANDA, or a 505(b)(2) application depending on the product’s relationship to the reference drug, dosage form, release characteristics, labeling, and clinical claims.[2]

References

1. DailyMed. (n.d.). Tenex: Guanfacine hydrochloride tablet prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptides: Product-specific guidance and general ANDA requirements. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. §355(j).

5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.